"13 Spike 02" principal and interest payment and delisting announcement.
Release time:
2021-05-20
股票代码:600668 股票简称:尖峰集团 公告编号:临2019-035
债券简称:13尖峰02 债券代码:122344
浙江尖峰集团股份有限公司
“13尖峰02”本息兑付和摘牌公告
本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担个别及连带责任。
重要内容提示:
- 兑付债权登记日:2019年11月19日
- 债券停牌起始日:2019年11月20日
- 兑付资金发放日:2019年11月20日
- 摘牌日:2019年11月20日
浙江尖峰集团股份有限公司2013年公司债券(第二期)(以下简称“本期债券”)将于2019年11月20日开始支付2018年11月20日至2019年11月19日期间最后一个年度利息和本期债券的本金,为保证还本付息工作的顺利进行,现将有关事宜公告如下:
一、本期债券基本情况
1、债券名称:浙江尖峰集团股份有限公司2013年公司债券(第二期)。
2、债券简称及代码:13尖峰02,代码122344
3、发行人:浙江尖峰集团股份有限公司
4、发行规模:本期债券发行总额为人民币3亿元。根据《浙江尖峰集团股份有限公司公开发行公司债券(第二期)募集说明书》中所设定的投资者回售选择权条款,本期债券在回售登记期(2017年10月13日至2017年10月19日)进行回售申报登记,有效登记数量为46,300手,回售金额为4,630万元。2017年11月20日,公司已经支付了回售款,公司本期债券余额为25,370万元。
5、债券期限:本期债券的期限为5年(附第3年末发行人上调票面利率选择权和投资者回售选择权)。
6、债券发行批准机关及文号:中国证券监督管理委员会证监许可[2013]595号文件批准发行。
7、债券形式:实名制记账式
8、债券利率:本期债券票面利率为5.09%,采用单利按年计息,不计复利。每年付息一次,到期一次还本,最后一期利息随本金的兑付一起支付。
9、计息期限:本期债券计息期限自2014年11月20日至2019年11月19日止;若投资者行使回售选择权,则回售部分债券的计息期限自2014年11月20日至2017年11月19日止。
10、付息日:本期债券付息日为2015年至2019年每年的11月20日;若投资者行使回售选择权,则回售部分债券的付息日为2014年至2017年每年的11月20日(上述付息日如遇法定节假日,则顺延至下一个工作日;每次付息款项不另计利息)。
11、兑付日:本期债券兑付日为2019年11月20日;若投资者行使回售选择权,则回售部分债券的兑付日为2017年11月20日(上述兑付日如遇法定节假日,则顺延至下一个工作日,每次兑付款项不另计利息)。
12、信用级别:经联合信用评级有限公司综合评定,本期公司债券信用等级为AA+,发行人主体信用等级为AA。
13、上市时间和地点:本期债券于2014年12月11日在上海证券交易所上市交易。
14、负责债券登记、托管、委托债券派息和兑付的机构:中国证券登记结算有限责任公司上海分公司
二、本次本息兑付方案
根据公司《浙江尖峰集团股份有限公司公开发行公司债券(第二期)募集说明书》和《浙江尖峰集团股份有限公司2013年公司债券(第二期)票面利率公告》的约定,本期债券的票面利率为5.09%,每手“13尖峰02”(面值人民币1,000元)实际派发利息为人民币50.90元(含税),兑付本金为1,000元(含税)。本次兑付的本息总额为266,613,330.00元(含税)。
三、兑付债权登记日及兑付日
1、兑付债权登记日:2019年11月19日
2、债券停牌起始日:2019年11月20日
3、兑付资金发放日:2019年11月20日
4、摘牌日:2019年11月20日
四、兑付对象
本次兑息兑付对象为截止2019年11月19日下午上海证券交易所收市后,在中国证券登记结算有限责任公司上海分公司(以下简称“中证登上海分公司”)登记在册的全体“13尖峰02”公司债券的持有人。
五、兑付、兑息办法
(1)本公司已与中证登上海分公司签订了《委托代理债券兑付、兑息协议》,委托中证登上海分公司进行债券兑付、兑息。公司将在兑付资金发放日前第二个交易日16:00前将本期债券本金及利息足额划付至中证登上海分公司指定的银行账户。如本公司未按时足额将债券兑付、兑息资金划入中证登上海分公司指定的银行账户,则中证登上海分公司将根据协议终止委托代理债券兑付、兑息服务,后续兑付、兑息工作由本公司自行负责办理,相关实施事宜以本公司的公告为准。
(2)中证登上海分公司在收到款项后,通过资金结算系统将债券本金及利息 划付给相应的兑付机构(证券公司或中证登上海分公司认可的其他机构),投资者于兑付机构领取债券本金及利息。
六、关于投资者缴纳本期债券利息所得税的说明
(一)关于向个人投资者征收企业债券利息所得税的说明
根据《中华人民共和国个人所得税法》以及其他相关税收法规和文件的规定,本期债券个人投资者应缴纳公司债券个人利息收入所得税。本期债券利息个人所得税将由各兑付机构负责代扣代缴,并直接向各兑付机构所在地的税务部门缴付。本期债券的个人利息所得税征缴说明如下:
1、纳税人:本期债券的个人投资者;
2、征税对象:本期债券的利息所得;
3、征税税率:按利息额的20%征收;
4、征税环节:个人投资者在兑付机构领取利息时由兑付机构一次性扣除;
5、代扣代缴义务人:负责本期债券付息工作的各兑付机构。
6、本期债券利息税的征管部门:各兑付机构所在地的税务部门。
(二)关于向非居民企业征收企业债券利息所得税的说明
根据2018年11月7日发布的《关于境外机构投资境内债券市场企业所得税增值税政策的通知》,自2018年11月7日起至2021年11月6日止,对境外机构投资境内债券市场取得的债券利息收入暂免征收企业所得税和增值税。上述暂免征收企业所得税的范围不包括境外机构在境内设立的机构、场所取得的与该机构、场所有实际联系的债券利息。
(三)其他投资者缴纳公司债券利息所得税的说明
对于本期债券其他投资者,其债券利息所得税自行缴纳。
七、本期债券兑付相关机构
1、发行人:浙江尖峰集团股份有限公司
住所:浙江省金华市婺江东路88号
法定代表人:蒋晓萌
联系人:朱坚卫、余果
联系电话:0579-82320582、82324699
传真:0579-82320582、82324699
2、主承销商:浙商证券股份有限公司
法定代表人:吴承根
住所:杭州市江干区五星路201号
联系人:华佳、马岩笑
联系电话:0571-87902082、87903124
传真:0571-87903239
3、托管人:中国证券登记结算有限责任公司上海分公司
地址:上海市陆家嘴东路166号中国保险大厦3层
联系人:徐瑛
电话:021-68870114
传真:021-68875802
邮政编码:200120
特此公告。
浙江尖峰集团股份有限公司
董 事 会
二〇一九年十一月十一日
More information
Pharmaceutical Company Established New Drug R & D Promotion Committee
Recently, the new drug research and development promotion committee of Jianfeng pharmaceutical company was formally established, which will be responsible for promoting the new drug research and development progress of pharmaceutical companies and subordinate enterprises, and coordinating the new drug research and development work of various departments and subordinate enterprises. The New Drug Promotion Committee is headed by Huang Jinlong, deputy general manager of the group and general manager of the pharmaceutical company, and Jiang Hong, deputy general manager of the pharmaceutical company, is headed by Pang Xiong, Shi Cunyuan, Xu Lizhen, Yu Jingjing, Zheng Kunwu, Feng Lixiang, Kang Litao, Li Qian, Wu Chonggui, Zhai Tsunami, Huang Fang and Tong Xiaojun. The committee has an office, and Shi Cunyuan is also the director of the office, responsible for the supervision, communication, and coordination of the company's new drug research and development projects. The main responsibilities of the new drug promotion committee include: organizing the establishment and improvement of the R & D project management system and relevant regulations of the pharmaceutical company; organizing the formulation of the development plan of the new drug R & D project of the pharmaceutical company and supervising the implementation; making decisions on project initiation and participating in project evaluation; supervising the management of new drug R & D of the pharmaceutical company and providing guidance; Responsible for the process management of new drug R & D projects and the promotion and coordination of new drug R & D; carry out the assessment of new drug research and development projects; issue the responsibility system assessment and task statement of new drug research and development projects; be responsible for solving major technical problems in the process of new drug research and development; be responsible for the research and improvement of the management mode of research and development projects of pharmaceutical companies; be responsible for the future trend analysis of new drug research and development projects; review the major scientific research achievements of pharmaceutical companies and put forward reward suggestions. Huang Jinlong said that the research and development of new drugs is an important foundation for the healthy development of the pharmaceutical industry and is a systematic project. Jianfeng Pharmaceutical has always attached great importance to the research and development of new drugs, but there is still a certain gap between the progress of research and development and the development process of the enterprise, and the lack of coordination in the research and development process also affects the progress and quality of new drug research and development to a certain extent. The purpose of the establishment of the New Drug Research and Development Promotion Committee is to solve the progress of new drug research and development, to find and solve problems in time, to implement more targeted, and to effectively integrate enterprise resources, improve the speed and quality of new drug research and development, and make good product reserves for the healthy development of pharmaceutical companies. (Reporter Ni Yingzhen)
2020
09-11
Jianfeng Pharmaceutical ranks among the top 100 Chinese pharmaceutical industries in 2019
On August 25, the "2019 Top 100 Series List of China's Pharmaceutical Industry" was released in Kunming. Zhejiang Jianfeng Pharmaceutical Company was shortlisted as one of the top 100 enterprises in China's pharmaceutical industry. The product Berunning (Olopatadine Hydrochloride Eye Drops) was selected as the "Most Growing Product Brand" of China's pharmaceutical industry ". The "Top 100 Pharmaceutical Industry Series List" was evaluated and released by Guangzhou Punctuation Pharmaceutical Information Co., Ltd., a subsidiary of the Southern Institute of Pharmaceutical Economics of the State Drug Administration, and is known as the "Oscar in Chinese Pharmaceutical Industry. Southern Institute is the earliest institution in China that specializes in pharmaceutical industry policy and market economy research, pharmaceutical market research, pharmaceutical economic data analysis and research, and pharmaceutical professional media publishing. It is in the field of market information value-added services and media communication and marketing services in China's pharmaceutical and health industry., The field of professional quality improvement has extremely extensive influence. The "Top 100 Pharmaceutical Industry" is comprehensively evaluated by the company's annual pharmaceutical industry sales revenue, total profit and R & D investment results. On the same day, the "most growing product brand" of Chinese medicine selected by the Southern Institute's media "Pharmaceutical Economic News" was released simultaneously. Spike Pharmaceuticals product Beirunning (Olopatadine Hydrochloride Eye Drops) was selected. (Xu Yuting)
2020
09-01
Company Disclosure 2020 Semi-Annual Report
On August 28, the Group held the 16th meeting of the 10th Board of Directors of the Company by means of communication, and considered and adopted the "2020 Semi-Annual Report of Jianfeng Group" and the "Proposal on Changes in the Company's Accounting Policy". On August 29, the Company's 2020 semi-annual report was publicly disclosed on the Shanghai Stock Exchange and the Shanghai Securities News and China Securities News. In the first half of the year, the Group focused on the general policy of "grasping projects, making up for shortcomings, improving quality and efficiency, and constantly improving the core competitive advantage", and on the basis of doing a good job in epidemic prevention and control, the Group seized the resumption of work and production, accelerated project construction, and enhanced the core competitiveness of enterprises. In the first half of 2020, the company achieved total operating income of 1.44 billion yuan, net profit attributable to shareholders of 0.368 billion yuan, net profit per share of 1.07 yuan. As of the end of June 2020, the Company's total assets were $5.892 billion, net assets were $4.068 billion, and net assets per share were $11.82. From February to April, affected by the epidemic, the national project construction progress slowed down, cement market demand decreased; after May, the epidemic was effectively controlled, infrastructure investment continued to recover, the real estate industry continued to pick up, cement sales steadily rebounded. During the outbreak, Daye Peak completed the technical transformation projects such as the cold machine, cement mill, into the desulfurization tower anti-corrosion transformation, to ensure the efficient operation of the production equipment after the resumption of work. Yunnan peak rotary kiln production, cement production and other major technical and economic indicators of steady rise; comply with market trends, timely adjustment of marketing policies. Guizhou Jianfeng has promoted the project infrastructure construction, equipment installation and commissioning, raw material bidding and other work in an orderly manner, and through preliminary publicity to enhance the popularity of the Jianfeng brand in the local area, and make a series of preparations for the transformation from project construction to production and operation. In the first half of 2020, the reform of China's medical and health system continued to deepen, and new policies were introduced intensively. Peak Pharmaceuticals and its subsidiaries in the epidemic prevention work at the same time in the first time to achieve the resumption of production, and actively organize donations to support the fight against the epidemic, was named the annual "war epidemic star" the most socially responsible pharmaceutical enterprises. In the first half of the year, Jianfeng Pharmaceutical continued to increase the introduction and development of varieties, and JFAN-1001 applied for clinical application of new anti-tumor drugs. At present, it has obtained the notice of approval for clinical trials. Optimize the production process of API workshop and further shorten the production cycle of raw materials. Continue to improve product sales policies and strengthen market channel control. Shanghai North Carolina further straightened out the internal management structure, production and marketing convergence more smoothly, continue to promote the construction of Anhui North Carolina and Anhui Zhongwang Phase II technical transformation project, promote the peak pharmaceutical raw materials, preparations integration of industrial upgrading strategy. Other business segments of the company actively responded to the challenge of the new crown epidemic and carried out production and operation activities in a standardized and orderly manner. Tianjin natural products company vigorously explore the international and domestic markets, sales revenue to achieve steady growth. Peak Health focuses on the basic idea of "sales orientation, burden reduction and efficiency improvement, fine-grained savings, cost reduction and efficiency enhancement" to effectively improve the operational efficiency of enterprises. Jianfeng International Trade has actively developed new storage business varieties and achieved practical results, and has become the first enterprise in Jinhua to formally obtain the qualification of "network freight. Peak cable seizes the special needs of communication cables such as subways, vigorously promotes large logarithmic cables for subways, and strives to achieve the long tail effect. On the same day, the company also held the 10th meeting of the Ninth Board of Supervisors and reviewed and approved relevant reports. (residual fruit)
2020
09-01
The company organizes new employee induction training
From August 12 to 14, in order to strengthen the training of talents in the group and improve the comprehensive quality of new employees, Jiang Xiaomeng, secretary of the party committee and chairman of the group company, Yu Jianhong, general manager, and other leaders and heads of relevant enterprises and departments conducted a three-day induction training for new employees. New employees from foreign enterprises such as Guizhou Huangping Peak, Daye Peak and Shanghai North Carolina participated simultaneously through online methods. In the course of corporate culture, General Manager Yu Jianhong started from the history of the development and struggle of the peak, divided into five stages: hard work, determined reform, diversified development, strategic adjustment, and strategic development, and introduced in detail the development process of the group company and the current industrial layout., The results achieved; from the aspects of enterprise spirit, vision, development philosophy, values, business philosophy, etc, this paper introduces the peak corporate culture rooted in 62 years of history and inherited in the blood; from the perspective of an enterprise manager and old employees, he speaks a lot of truth to the new employees and puts forward a lot of hopes and suggestions. Chairman Jiang Xiaomeng took "How New Employees Achieve Win-Win with Enterprises" as the topic, and proposed that the key to the success of an enterprise lies in how to select, retain, educate and employ people. Peak and employees complement each other. Peak can achieve today's achievements and the struggle of generations of peak people are inseparable. He also taught new employees the basic concepts that need to be understood, the basic qualities that need to be possessed and the sense of hardship in entering the new environment through 16 key words, and combined with his own experience and quoting from others, he analyzed the core elements of success, the signs of a successful career, the personal qualities that need to be possessed for success, and the importance of establishing a personal knowledge management system, it expresses the ardent hope of new employees to adjust their mentality, keep learning, clear goals, clear dreams, cultivate win-win thinking, and grow up together with the peak. The heads of the human resources department of the group company, the safety management office of the group company, and the comprehensive department of the pharmaceutical company also taught the new employees the corporate rules and regulations and the "Employee Handbook", safety knowledge and professional ethics. The new employees also visited the group exhibition hall and had a deeper understanding of the development history and enterprise achievements of the peak. After the training, the human resources department also organized an examination to test the training effect. (Reporter Chen Shengmu)
2020
08-21
According to this newspaper, through the interconnection monitoring of the transportation department in Zhejiang province, the network freight platform of peak international trading company passed the online service capability audit, interface access audit, eight capability identification and other audit procedures, and successfully obtained the road transportation business license with the qualification of "network freight" on July 2. It is understood that Jianfeng International Trade is currently the first enterprise in Jinhua and Quzhou to obtain this qualification.
2020
08-05
News from our newspaper On July 21, Xi Jinping, General Secretary of the Central Committee of the Communist Party of China, President of the State, and Chairman of the Central Military Commission hosted a symposium for entrepreneurs in Beijing and delivered an important speech. Over the past few days, the General Secretary's speech has aroused strong repercussions in all walks of life. On July 23, Jiang Xiaomeng, chairman of the group company, said in an interview with Jinhua TV that the general secretary's speech was calm and inspiring, and pointed out the direction of future work for entrepreneurs.
2020
08-05